Biocorp Production

Biocorp Production Debt

Delisted

The Debt of Biocorp Production (ALCOR.PA) as of Oct 30, 2026 is 5.78 M EUR. In the previous year, Debt was 4.20 M EUR — a change of 37.70% (higher).

Debt

5.78 MEUR

YoY

37.70%

Last updated:

In 2022, Biocorp Production's total debt was 5.78 M EUR, a 37.70% change from the 4.20 M EUR total debt recorded in the previous year.

The Biocorp Production Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2015
3.33 M EUR
Jan 1, 2016
2.95 M EUR
Jan 1, 2017
3.87 M EUR
Jan 1, 2018
5.31 M EUR
Jan 1, 2019
4.20 M EUR
Jan 1, 2020
5.85 M EUR
Jan 1, 2021
4.20 M EUR
Jan 1, 2022
5.78 M EUR
The Biocorp Production Debt history
YEARDebtYoY
5.78 MEUR+37.70%
4.20 MEUR-28.34%
5.85 MEUR+39.42%
4.20 MEUR-20.94%
5.31 MEUR+37.21%
3.87 MEUR+31.10%
2.95 MEUR-11.37%
3.33 MEUR-5.36%
3.52 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocorp Production Stock analysis

What does Biocorp Production do? Biocorp Production SA is a French company in the medical technology industry that manufactures innovative solutions for drug administration and injections. It was founded in 2004 under the name Biocorp sur mesure by Eric Dessertenne and later transformed into Biocorp Production SA. The business model of Biocorp Production SA is to produce innovative medical devices that can be used in medical applications. The company specializes in the development of smart devices that support injection administration. The devices produced by Biocorp can be operated by medical professionals or by patients themselves. One of the core areas of Biocorp Production SA is the development of smart medical technologies that aid in medication management. One such product is Vyoo, a device that assists patients in injecting medications. It is a digital device that facilitates injection administration and makes dosing safer. In addition to developing smart devices, Biocorp also offers other services, such as in the field of clinical trials for medical applications. The company works closely with pharmaceutical companies to develop medical devices and solutions for drug administration. Another important product is Mallya, an intelligent insulin administration system specifically designed for diabetes patients. It enables automated insulin administration tailored to the patient's needs, thereby improving their quality of life. Furthermore, Biocorp Production SA is also involved in the field of wearable medical technology. One example of a wearable device is Easylog, an electronic device for monitoring medical conditions. This device is particularly useful for patients with chronic diseases such as diabetes or asthma. Over the years, Biocorp Production SA has received numerous awards for its innovative products and services. For example, the company received the Innovation Award at the "Innovation Awards" in Paris in 2017 for the Mallya device. Overall, the company currently employs over 60 employees and has its headquarters in Issoire. It has branches in Germany and the USA. The products of Biocorp Production SA are sold in more than 80 countries worldwide. In summary, Biocorp Production SA is a leading provider of smart medical devices for drug administration and injections. The company strives to develop innovative solutions for the medical industry that are tailored to the needs of patients and medical professionals. With the products of Biocorp Production SA, medication administration becomes safer, easier, and more accurate. Biocorp Production is one of the most popular companies on Eulerpool.

Debt Details

Understanding Biocorp Production's Debt Structure

Biocorp Production's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Biocorp Production's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Biocorp Production’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Biocorp Production’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Biocorp Production stock

Debt of Biocorp Production is 5.78 M EUR in 2022.

Debt of Biocorp Production changed from 4.20 M EUR to 5.78 M EUR, representing a 37.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Biocorp Production since 2006 – with annual values, charts, and detailed analysis.

Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Biocorp Production historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biocorp Production

All Key Metrics — Biocorp Production